Acute Pain - Pipeline Review, H2 2016

  • ID: 3837856
  • Report
  • 194 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Adynxx, Inc.
  • Antibe Therapeutics, Inc.
  • Cytogel Pharma, LLC
  • KPI Therapeutics, Inc.
  • Orbis Biosciences Inc
  • Recro Pharma, Inc.
  • MORE
Acute Pain - Pipeline Review, H2 2016

Summary

‘Acute Pain - Pipeline Review, H2 2016’, provides an overview of the Acute Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acute Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Pain and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acute Pain
- The report reviews pipeline therapeutics for Acute Pain by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Acute Pain therapeutics and enlists all their major and minor projects
- The report assesses Acute Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Acute Pain

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Acute Pain
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Acute Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Adynxx, Inc.
  • Antibe Therapeutics, Inc.
  • Cytogel Pharma, LLC
  • KPI Therapeutics, Inc.
  • Orbis Biosciences Inc
  • Recro Pharma, Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Acute Pain Overview

Therapeutics Development

Pipeline Products for Acute Pain - Overview

Pipeline Products for Acute Pain - Comparative Analysis

Acute Pain - Therapeutics under Development by Companies

Acute Pain - Therapeutics under Investigation by Universities/Institutes

Acute Pain - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Unknown Stage Products

Acute Pain - Products under Development by Companies

Acute Pain - Products under Investigation by Universities/Institutes

Acute Pain - Companies Involved in Therapeutics Development

AcelRx Pharmaceuticals, Inc.

Adynxx, Inc.

Amorsa Therapeutics Inc.

AnaBios Corporation

Anavex Life Sciences Corp.

AngioChem Inc.

Antibe Therapeutics, Inc.

AskAt Inc.

Cara Therapeutics, Inc.

Centrexion Therapeutics Corp

Charleston Laboratories, Inc.

ChironWells GmbH

Crescita Therapeutics Inc.

Cytogel Pharma, LLC

Dompe Farmaceutici S.p.A.

Grunenthal GmbH

Iroko Pharmaceuticals, LLC

KemPharm, Inc.

KPI Therapeutics, Inc.

Laboratorios Del Dr. Esteve S.A.

Mallinckrodt Plc

Nanomerics Ltd

Nanotherapeutics, Inc.

Orbis Biosciences Inc

Orexo AB

Orion Oyj

Pacira Pharmaceuticals, Inc.

Phosphagenics Limited

Recro Pharma, Inc.

Scilex Pharmaceuticals, Inc.

Shulov Innovative Science Ltd.

Syntrix Biosystems, Inc.

Thar Pharmaceuticals, Inc.

Trevena, Inc.

Yungjin Pharm. Co., Ltd.

Acute Pain - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(acetaminophen + benzhydrocodone hydrochloride) IR - Drug Profile

(acetaminophen + hydrocodone bitartarate) ER - Drug Profile

(acetaminophen + tramadol hydrochloride) SR - Drug Profile

(buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile

(celecoxib + tramadol hydrochloride) - Drug Profile

AAT-076 - Drug Profile

alfentanil hydrochloride - Drug Profile

AMS-410 FA - Drug Profile

ANAVEX-1037 - Drug Profile

ANAVEX-1066 - Drug Profile

ANAVEX-1067 - Drug Profile

ANAVEX-1079 - Drug Profile

ANAVEX-1519 - Drug Profile

ANG-2002 - Drug Profile

ARX-04 - Drug Profile

ATB-352 - Drug Profile

AYX-1 - Drug Profile

BBI-11008 - Drug Profile

celecoxib - Drug Profile

CL-108 - Drug Profile

CR-4056 - Drug Profile

Cyt-1010 - Drug Profile

dexmedetomidine hydrochloride - Drug Profile

DF-2593A - Drug Profile

difelikefalin - Drug Profile

Drug for Acute Pain - Drug Profile

ECP-1014 - Drug Profile

ET-1 - Drug Profile

FY-101C - Drug Profile

FY-103B - Drug Profile

grapiprant - Drug Profile

HPI-201 - Drug Profile

HS-731 - Drug Profile

ibuprofen - Drug Profile

ibuprofen - Drug Profile

ibuprofen - Drug Profile

ketamine hydrochloride - Drug Profile

lidocaine hydrochloride - Drug Profile

meloxicam - Drug Profile

meloxicam - Drug Profile

meloxicam ER - Drug Profile

Monoclonal Antibody to Inhibit TGF-Beta-1 for Acute Pain and Chronic Pancreatitis Pain - Drug Profile

MR-309 - Drug Profile

NM-0127 - Drug Profile

oliceridine - Drug Profile

Omnitram - Drug Profile

Peptides to Target TRPV1 for Pain and Itch - Drug Profile

prednisone - Drug Profile

Prostatic Acid Phosphatase - Drug Profile

RO-656570 - Drug Profile

Small Molecule to Block Nav1.9 Channel for Pain - Drug Profile

Small Molecules to Block Nav 1.7 for Pain - Drug Profile

Small Molecules to Block Nav 1.8 for Pain - Drug Profile

Synthetic Peptides to Target Mu Opioid Receptor and Delta Opioid Receptor for Pain - Drug Profile

T-109 - Drug Profile

tapentadol hydrochloride - Drug Profile

TRV-734 - Drug Profile

U-2902 - Drug Profile

VPX-595 - Drug Profile

ZEP-3 - Drug Profile

Acute Pain - Dormant Projects

Acute Pain - Discontinued Products

Acute Pain - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Number of Products under Development for Acute Pain, H2 2016

Number of Products under Development for Acute Pain - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Development by Companies, H2 2016 (Contd..1)

Number of Products under Development by Companies, H2 2016 (Contd..2)

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Comparative Analysis by Unknown Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016 (Contd..1)

Products under Development by Companies, H2 2016 (Contd..2)

Products under Development by Companies, H2 2016 (Contd..3)

Products under Investigation by Universities/Institutes, H2 2016

Acute Pain - Pipeline by AcelRx Pharmaceuticals, Inc., H2 2016

Acute Pain - Pipeline by Adynxx, Inc., H2 2016

Acute Pain - Pipeline by Amorsa Therapeutics Inc., H2 2016

Acute Pain - Pipeline by AnaBios Corporation, H2 2016

Acute Pain - Pipeline by Anavex Life Sciences Corp., H2 2016

Acute Pain - Pipeline by AngioChem Inc., H2 2016

Acute Pain - Pipeline by Antibe Therapeutics, Inc., H2 2016

Acute Pain - Pipeline by AskAt Inc., H2 2016

Acute Pain - Pipeline by Cara Therapeutics, Inc., H2 2016

Acute Pain - Pipeline by Centrexion Therapeutics Corp, H2 2016

Acute Pain - Pipeline by Charleston Laboratories, Inc., H2 2016

Acute Pain - Pipeline by ChironWells GmbH, H2 2016

Acute Pain - Pipeline by Crescita Therapeutics Inc., H2 2016

Acute Pain - Pipeline by Cytogel Pharma, LLC, H2 2016

Acute Pain - Pipeline by Dompe Farmaceutici S.p.A., H2 2016

Acute Pain - Pipeline by Grunenthal GmbH, H2 2016

Acute Pain - Pipeline by Iroko Pharmaceuticals, LLC, H2 2016

Acute Pain - Pipeline by KemPharm, Inc., H2 2016

Acute Pain - Pipeline by KPI Therapeutics, Inc., H2 2016

Acute Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H2 2016

Acute Pain - Pipeline by Mallinckrodt Plc, H2 2016

Acute Pain - Pipeline by Nanomerics Ltd, H2 2016

Acute Pain - Pipeline by Nanotherapeutics, Inc., H2 2016

Acute Pain - Pipeline by Orbis Biosciences Inc, H2 2016

Acute Pain - Pipeline by Orexo AB, H2 2016

Acute Pain - Pipeline by Orion Oyj, H2 2016

Acute Pain - Pipeline by Pacira Pharmaceuticals, Inc., H2 2016

Acute Pain - Pipeline by Phosphagenics Limited, H2 2016

Acute Pain - Pipeline by Recro Pharma, Inc., H2 2016

Acute Pain - Pipeline by Scilex Pharmaceuticals, Inc., H2 2016

Acute Pain - Pipeline by Shulov Innovative Science Ltd., H2 2016

Acute Pain - Pipeline by Syntrix Biosystems, Inc., H2 2016

Acute Pain - Pipeline by Thar Pharmaceuticals, Inc., H2 2016

Acute Pain - Pipeline by Trevena, Inc., H2 2016

Acute Pain - Pipeline by Yungjin Pharm. Co., Ltd., H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Acute Pain - Dormant Projects, H2 2016

Acute Pain - Dormant Projects (Contd..1), H2 2016

Acute Pain - Dormant Projects (Contd..2), H2 2016

Acute Pain - Dormant Projects (Contd..3), H2 2016

Acute Pain - Dormant Projects (Contd..4), H2 2016

Acute Pain - Dormant Projects (Contd..5), H2 2016

Acute Pain - Dormant Projects (Contd..6), H2 2016

Acute Pain - Discontinued Products, H2 2016

Acute Pain - Discontinued Products (Contd..1), H2 2016 181List of Figures

Number of Products under Development for Acute Pain, H2 2016

Number of Products under Development for Acute Pain - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Top 10 Routes of Administration, H2 2016

Number of Products by Stage and Top 10 Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Adynxx, Inc.
  • Antibe Therapeutics, Inc.
  • Cytogel Pharma, LLC
  • KPI Therapeutics, Inc.
  • Orbis Biosciences Inc
  • Recro Pharma, Inc.
  • MORE
According to our recently published report 'Acute Pain – Pipeline Review, H2 2016'; Acute Pain pipeline therapeutics constitutes close to 60 molecules. Out of which approximately 55 molecules are developed by Companies and remaining by the Universities/Institutes.

Furthermore, the publisher says: Acute Pain Acute pain is defined as the pain that occurs suddenly, quickly and severely. It lasts for a short period of time. It may lead to a rapid heart rate, anxiety, increases in breathing rate, blood pressure, dilated pupils and sweating. It is difficult to diagnose and treat acute pain. Symptoms of acute pain are usually associated with inflammation, tissue injury, a brief disease process, surgical procedure or childbirth. Acute pain can affect any body part. It usually affects the head, back, abdomen and chest. In acute pain, pain relief is brought about by the use of analgesics such as non steroidal anti-inflammatory drugs (NSAIDs).

The report 'Acute Pain – Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development for Acute Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews of key players involved in therapeutic development for Acute Pain and features dormant and discontinued projects. Currently, The molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 3, 1, 5, 8, 9, 28 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.
Note: Product cover images may vary from those shown
5 of 6
AcelRx Pharmaceuticals, Inc.
Adynxx, Inc.
Amorsa Therapeutics Inc.
AnaBios Corporation
Anavex Life Sciences Corp.
AngioChem Inc.
Antibe Therapeutics, Inc.
AskAt Inc.
Cara Therapeutics, Inc.
Centrexion Therapeutics Corp
Charleston Laboratories, Inc.
ChironWells GmbH
Crescita Therapeutics Inc.
Cytogel Pharma, LLC
Dompe Farmaceutici S.p.A.
Grunenthal GmbH
Iroko Pharmaceuticals, LLC
KemPharm, Inc.
KPI Therapeutics, Inc.
Laboratorios Del Dr. Esteve S.A.
Mallinckrodt Plc
Nanomerics Ltd
Nanotherapeutics, Inc.
Orbis Biosciences Inc
Orexo AB
Orion Oyj
Pacira Pharmaceuticals, Inc.
Phosphagenics Limited
Recro Pharma, Inc.
Scilex Pharmaceuticals, Inc.
Shulov Innovative Science Ltd.
Syntrix Biosystems, Inc.
Thar Pharmaceuticals, Inc.
Trevena, Inc.
Yungjin Pharm. Co., Ltd.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll